EGFR and prostate cancer: We therefore determined if signaling pathways downstream of EGFR activation that have also been previously implicated in LDLR expression, such as Akt11 in glioblastoma and STAT322 in prostate cancer, differed in MDA231 (Fig. 3a and Supplementary Fig. 3) and MDA468 cells (Fig. 3c).